These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30286952)

  • 1. Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
    Karypidou K; Ribone SR; Quevedo MA; Persoons L; Pannecouque C; Helsen C; Claessens F; Dehaen W
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3472-3476. PubMed ID: 30286952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
    Ohnishi K; Hattori Y; Kobayashi K; Akaji K
    Bioorg Med Chem; 2019 Jan; 27(2):425-435. PubMed ID: 30558861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.
    Ramajayam R; Tan KP; Liu HG; Liang PH
    Bioorg Med Chem; 2010 Nov; 18(22):7849-54. PubMed ID: 20947359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment.
    Zhang L; Lin D; Kusov Y; Nian Y; Ma Q; Wang J; von Brunn A; Leyssen P; Lanko K; Neyts J; de Wilde A; Snijder EJ; Liu H; Hilgenfeld R
    J Med Chem; 2020 May; 63(9):4562-4578. PubMed ID: 32045235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.
    Galasiti Kankanamalage AC; Kim Y; Damalanka VC; Rathnayake AD; Fehr AR; Mehzabeen N; Battaile KP; Lovell S; Lushington GH; Perlman S; Chang KO; Groutas WC
    Eur J Med Chem; 2018 Apr; 150():334-346. PubMed ID: 29544147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study.
    Berry M; Fielding BC; Gamieldien J
    Viruses; 2015 Dec; 7(12):6642-60. PubMed ID: 26694449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human rhinovirus 3C protease as a potential target for the development of antiviral agents.
    Wanga QM; Chen SH
    Curr Protein Pept Sci; 2007 Feb; 8(1):19-27. PubMed ID: 17305557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.
    Namoto K; Sirockin F; Sellner H; Wiesmann C; Villard F; Moreau RJ; Valeur E; Paulding SC; Schleeger S; Schipp K; Loup J; Andrews L; Swale R; Robinson M; Farady CJ
    Bioorg Med Chem Lett; 2018 Mar; 28(5):906-909. PubMed ID: 29433930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors.
    Zaher NH; Mostafa MI; Altaher AY
    Acta Pharm; 2020 Jun; 70(2):145-159. PubMed ID: 31955138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors.
    Im I; Lee ES; Choi SJ; Lee JY; Kim YC
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3632-6. PubMed ID: 19464175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.
    Kawatkar SP; Gagnon M; Hoesch V; Tiong-Yip C; Johnson K; Ek M; Nilsson E; Lister T; Olsson L; Patel J; Yu Q
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3248-3252. PubMed ID: 27265257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.
    Ghosh AK; Takayama J; Rao KV; Ratia K; Chaudhuri R; Mulhearn DC; Lee H; Nichols DB; Baliji S; Baker SC; Johnson ME; Mesecar AD
    J Med Chem; 2010 Jul; 53(13):4968-79. PubMed ID: 20527968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
    Yang S; Chen SJ; Hsu MF; Wu JD; Tseng CT; Liu YF; Chen HC; Kuo CW; Wu CS; Chang LW; Chen WC; Liao SY; Chang TY; Hung HH; Shr HL; Liu CY; Huang YA; Chang LY; Hsu JC; Peters CJ; Wang AH; Hsu MC
    J Med Chem; 2006 Aug; 49(16):4971-80. PubMed ID: 16884309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus.
    Goetz DH; Choe Y; Hansell E; Chen YT; McDowell M; Jonsson CB; Roush WR; McKerrow J; Craik CS
    Biochemistry; 2007 Jul; 46(30):8744-52. PubMed ID: 17605471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
    Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.
    Prior AM; Kim Y; Weerasekara S; Moroze M; Alliston KR; Uy RA; Groutas WC; Chang KO; Hua DH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6317-20. PubMed ID: 24125888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimize the interactions at S4 with efficient inhibitors targeting 3C proteinase from enterovirus 71.
    Zhang L; Huang G; Cai Q; Zhao C; Tang L; Ren H; Li P; Li N; Huang J; Chen X; Guan Y; You H; Chen S; Li J; Lin T
    J Mol Recognit; 2016 Nov; 29(11):520-527. PubMed ID: 27185390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.
    Lai L; Han X; Chen H; Wei P; Huang C; Liu S; Fan K; Zhou L; Liu Z; Pei J; Liu Y
    Curr Pharm Des; 2006; 12(35):4555-64. PubMed ID: 17168761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
    Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Reich SH; Marakovits JT; Prins TJ; Zhou R; Tikhe J; Littlefield ES; Bleckman TM; Wallace MB; Little TL; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; DeLisle DM; Worland ST
    J Med Chem; 1998 Jul; 41(15):2819-34. PubMed ID: 9667971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.